44 7897 074717Review Article - Journal of Clinical Respiratory Medicine (2025) Volume 9, Issue 4
Vap in immunocompromised: Diagnostics, therapy, prevention.
Erik Jansen*
Department of Pulmonary Medicine, VU University Medical Center, Netherlands
- *Corresponding Author:
- Erik Jansen
Department of Pulmonary Medicine
VU University Medical Center, Netherlands.
E-mail: erik.jansen@medic.vu.nl
Received : 01-Jul-2025, Manuscript No. AAJCRM-25-284; Editor assigned : 03-Jul-2025, PreQC No. AAJCRM-25-284(PQ); Reviewed : 23-Jul-2025, QC No AAJCRM-25-284; Revised : 01-Aug-2025, Manuscript No. AAJCRM-25-284(R); Published : 12-Aug-2025 , DOI : 10.35841/AAJCRM-9.4.284
Citation: Jansen E. Vap in immunocompromised: Diagnostics, therapy, prevention. J Clin Resp Med. 2025;09(04):284.
Introduction
Pulmonary infections represent a formidable challenge in immunocompromised patients, where the host's weakened defenses make them susceptible to a broad spectrum of pathogens with often subtle clinical presentations. Ventilator-associated pneumonia (VAP) in particular presents unique diagnostic and management hurdles in this vulnerable group. Accurate diagnosis of VAP is tough, often requiring invasive sampling to differentiate infection from other pulmonary infiltrates [1].
Diagnosing pulmonary infections in immunocompromised patients is a a real puzzle, given the broad spectrum of potential pathogens and often subtle clinical presentations. Let's break it down: conventional methods like sputum cultures frequently fall short, pushing us towards more advanced techniques like bronchoalveolar lavage, PCR-based assays, and even next-generation sequencing. The goal is to get precise pathogen identification quickly to guide targeted therapy and improve patient prognosis [2].
Preventing ventilator-associated pneumonia is a cornerstone of critical care. Here's the thing: a bundle approach, consistently applied, makes a huge difference. What this really means is integrating elements like head-of-bed elevation, daily sedation interruption, spontaneous breathing trials, oral care with chlorhexidine, and peptic ulcer prophylaxis. Each component, though seemingly small, collectively reduces the risk significantly, directly impacting patient outcomes and healthcare costs [3].
Invasive fungal pulmonary infections are a serious threat to immunocompromised patients, often leading to high morbidity and mortality. Let's break it down: early and accurate diagnosis is crucial, utilizing advanced imaging, molecular tests, and biomarker detection alongside conventional cultures. What this really means is prompt initiation of appropriate antifungal therapy, often empirical, followed by tailored regimens once specific pathogens like Aspergillus or Candida are identified. Vigilance and rapid response are key [4].
Viral pulmonary infections pose a significant challenge in immunocompromised individuals, with a wide range of viruses causing severe disease. Here's the thing: while some, like Cytomegalovirus (CMV) or influenza, are well-known, others like respiratory syncytial virus or parainfluenza can also be devastating. What this really means is diagnostic strategies need to be comprehensive, often involving PCR-based detection from respiratory samples. Treatment often relies on antiviral agents where available, but supportive care remains paramount [5].
Antibiotic stewardship is crucial for managing ventilator-associated pneumonia, especially with the rising threat of antimicrobial resistance. Let's break it down: optimizing antibiotic use means rapid de-escalation of broad-spectrum therapy once culture results are available, and considering shorter courses of antibiotics. What this really means is a collaborative effort between intensivists, pharmacists, and microbiologists to ensure patients receive the right drug, at the right dose, for the right duration, minimizing collateral damage [6].
The diagnostic landscape for ventilator-associated pneumonia is evolving, moving beyond traditional cultures to faster, more precise methods. Here's the thing: emerging tools like molecular diagnostics (e.g., PCR, metagenomic sequencing), host biomarkers (e.g., procalcitonin, C-reactive protein), and rapid non-invasive techniques are showing promise. What this really means is a shift towards earlier, more accurate pathogen identification, which can facilitate targeted antibiotic therapy and potentially improve patient outcomes by reducing empiric broad-spectrum use [7].
COVID-19 significantly complicates pulmonary infections in immunocompromised patients, presenting with prolonged viral shedding, atypical presentations, and higher risk of severe disease. Let's break it down: these patients often require extended courses of antiviral therapy and are more susceptible to co-infections. What this really means is a tailored approach to diagnosis and management, considering their underlying immunosuppression and the potential for reduced vaccine effectiveness, making prevention and early intervention even more critical [8].
Understanding the lung microbiome is reshaping our perspective on ventilator-associated pneumonia. Here's the thing: it's not just about a single pathogen; shifts in the microbial community structure, dysbiosis, can predispose patients to infection. What this really means is that factors influencing the lung microbiome, like antibiotics and mechanical ventilation itself, play a role in VAP pathogenesis. This opens doors for novel preventive and therapeutic strategies targeting microbial balance, not just eradication [9].
Multidrug-resistant (MDR) bacterial pulmonary infections are a growing nightmare, particularly for immunocompromised patients. Let's break it down: these infections are incredibly difficult to treat due to limited effective antibiotic options, leading to higher mortality rates. What this really means is that aggressive surveillance, rapid diagnostic stewardship, and exploring novel antimicrobial agents or combinations are paramount. The global spread of MDR pathogens demands a coordinated effort to protect this vulnerable population [10].
Conclusion
Pulmonary infections, particularly ventilator-associated pneumonia (VAP), present significant challenges in immunocompromised patients. Accurate diagnosis is often difficult, requiring invasive sampling and advanced techniques like bronchoalveolar lavage, PCR, and next-generation sequencing to pinpoint pathogens beyond conventional cultures. Empirical therapy needs to be broad-spectrum, given the heightened risk of drug-resistant bacteria, atypical organisms, and the specific threats posed by invasive fungal and viral infections. Tailoring treatment quickly based on microbiologic results is critical for improving outcomes. Prevention strategies for VAP emphasize a bundle approach, integrating head-of-bed elevation, daily sedation interruption, spontaneous breathing trials, oral care with chlorhexidine, and peptic ulcer prophylaxis. Antibiotic stewardship is crucial to combat antimicrobial resistance, advocating for rapid de-escalation of broad-spectrum therapy and optimized treatment durations through collaborative efforts. The diagnostic landscape is evolving, with molecular diagnostics, host biomarkers, and rapid non-invasive techniques promising earlier and more precise pathogen identification, which can reduce empiric antibiotic use. Understanding the lung microbiome is also reshaping our perspective, recognizing that dysbiosis can predispose patients to VAP, suggesting novel preventive and therapeutic strategies beyond mere eradication. Furthermore, multidrug-resistant bacterial infections and the complexities of COVID-19 demand aggressive surveillance, rapid diagnostics, and tailored approaches in this vulnerable population. Vigilance and rapid response are paramount across all aspects of care.
References
References
- Marin HK, Scott TM, Brian WC. Diagnosis and management of ventilator-associated pneumonia in immunocompromised patients. Curr Opin Infect Dis. 2020 Dec;33(6):499-506.
Indexed at, Google Scholar, Crossref
- Sandra M, Frank R, Thomas S. Pulmonary Infections in Immunocompromised Patients: A Narrative Review of Diagnostic Approaches. J Clin Med. 2022 Aug 30;11(17):5133.
Indexed at, Google Scholar, Crossref
- Andre CK, Daniel JD, Marin HK. Strategies to Prevent Ventilator-Associated Pneumonia: A Narrative Review. Semin Respir Crit Care Med. 2020 Jun;41(3):362-371.
Indexed at, Google Scholar, Crossref
- Oliver AC, Jo-Anne HY, George RT3. Invasive Fungal Pulmonary Infections in Immunocompromised Patients: Diagnosis and Treatment. J Fungi (Basel). 2021 May 11;7(5):379.
Indexed at, Google Scholar, Crossref
- Jens G, Axel S, Christian E. Viral pulmonary infections in immunocompromised patients. Respir Med. 2021 Sep;186:106518.
Indexed at, Google Scholar, Crossref
- Ryan WS, David GC, Marin HK. Antibiotic Stewardship in Ventilator-Associated Pneumonia. Clin Chest Med. 2019 Sep;40(3):589-601.
Indexed at, Google Scholar, Crossref
- Mikael K, Anu K, Hanna-Riikka P. Newer diagnostic tools for ventilator-associated pneumonia. Curr Opin Infect Dis. 2021 Aug 1;34(4):367-374.
Indexed at, Google Scholar, Crossref
- Morten H, Line K, Marie L. COVID-19 in immunocompromised patients: a narrative review of current evidence. Front Immunol. 2022 Nov 25;13:999659.
Indexed at, Google Scholar, Crossref
- Robert PD, Kathleen AC, Susan PM. The lung microbiome in ventilator-associated pneumonia. Curr Opin Pulm Med. 2020 May;26(3):289-294.
Indexed at, Google Scholar, Crossref
- Matteo B, Chiara C, Michele R. Multidrug-resistant bacterial pulmonary infections in immunocompromised hosts: a global challenge. Lancet Infect Dis. 2021 Jan;21(1):e16-e26.